Cargando…

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial

BACKGROUND: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States who have previously responded to injectable somatostatin receptor ligands (iSRLs, octreotide or lanreotide). In previous phase 3 studies, the safety of OOC was shown to be consistent w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elenkova, Atanaska, Jensterle, Mojca, Kennedy, Laurence, Manning, Patrick, Melmed, Shlomo, Strasburger, Christian J, Samson, Susan, Nachtigall, Lisa, Fleseriu, Maria, Molitch, Mark E, Giustina, Andrea, Haviv, Asi, Biermasz, Nienke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625665/ http://dx.doi.org/10.1210/jendso/bvac150.1138

Ejemplares similares

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2021)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase
por: Fleseriu, Maria, et al.
Publicado: (2022)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2023)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study
por: Fleseriu, Maria, et al.
Publicado: (2020)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
por: Strasburger, Christian J, et al.
Publicado: (2016)

A Consensus Statement on acromegaly therapeutic outcomes
por: Melmed, Shlomo, et al.
Publicado: (2018)

New medical therapies on the horizon: oral octreotide
por: Biermasz, Nienke R.
Publicado: (2017)

Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

Octreotide-Resistant Acromegaly: Challenges and Solutions
por: Corica, Giuliana, et al.
Publicado: (2020)

A consensus on the diagnosis and treatment of acromegaly complications
por: Melmed, S., et al.
Publicado: (2012)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Development of a novel patient-reported measure for acromegaly: the Acro-TSQ
por: Fleseriu, Maria, et al.
Publicado: (2019)

Do We Need a Specific Guideline for Assessment and Improvement of Acromegaly Patients Adherence?
por: Kamusheva, Maria, et al.
Publicado: (2021)

An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
por: Fleseriu, Maria, et al.
Publicado: (2020)

PMON66 A Systematic Literature Review to Evaluate Extended Dosing Intervals in the Pharmacological Management of Acromegaly
por: Fleseriu, Professor Maria, et al.
Publicado: (2022)

The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
por: Klibanski, Anne, et al.
Publicado: (2009)

Effect of octreotide on endometriosis in acromegaly: Case report with review of literature
por: Singh, Seerat, et al.
Publicado: (2014)

Octreotide use for rescue of vision in a pregnant patient with acromegaly
por: Hannon, Anne Marie, et al.
Publicado: (2019)

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study
por: Giustina, Andrea, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_juvttvrpa3mng9hg7otb7fohja